Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-viral veto cell therapy - Cell Source

Next Previous
Drug Profile

Anti-viral veto cell therapy - Cell Source

Alternative Names: T-central memory Veto Cell - Cell Source; TCM Veto Cell - Cell Source; Veto Cell - Cell Source

Latest Information Update: 07 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Cell Source
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Graft-versus-host disease; Viral infections
  • Preclinical Sickle cell anaemia
  • No development reported Transplant rejection

Most Recent Events

  • 19 Mar 2021 Cell Source receives issuance notices for two patents from the USPTO for Veto Cell technology in USA
  • 01 Mar 2021 Preclinical trials in Sickle cell anaemia in Israel (IV)
  • 08 Aug 2019 Phase-I/II clinical trials in Viral infections (Prevention, In adolescents, In adults) in USA (IV) (NCT03622788)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top